Several studies have shown that plasma copper concentrations are increased
in various carcinomas. Zinc acts as a cellular growth protector, including
growth of neoplastic cells, and its deficiency was demonstrated to be invol
ved in several stages of malignant transformation. However, the usefulness
of the serum zinc and copper determinations in cancer prevention, detection
, monitoring treatment, and prognosis requires further investigations. The
aim of the present study was to compare the serum copper and zinc levels in
patients with cancer of the lung (PC), breast (BC), gastrointestinal tract
(GIC), and gynecological (GYNC) malignancy with progress of the disease. T
he results of the study have shown a significant increase in the mean total
serum Cu levels and the serum Cu/Zn ratio in all patient groups with cance
r compared to a control group. Increased mean serum concentrations and Cu/Z
n ratios were found in the whole group (ALLC), and for the GIC and GYNC gro
ups with local as well as metastasized (Meta) disease in comparison with th
e control group. The mean serum concentrations of Zn were decreased only in
metastasized ALLC and GYNC groups.